Fortress Biotech Inc expected to post a loss of $1.73 a share - Earnings Preview

Fortress Biotech

10/05/2024 12:40

* Fortress Biotech Inc  FBIO.OQ   FBIO.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 13
(estimated) for the period ending March 31 2024
    * The Bay Harbor Islands Florida-based  company is expected
to
report a 13.7% increase in revenue to $14.131 million from
$12.43 million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Fortress Biotech Inc is
for a
loss of $1.73 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 20.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Fortress
Biotech
Inc is $24.00​, above​ its last closing price of $1.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.67       -1.97      -1.28     Beat    34.9
 Sep. 30 2023  -3.12       -3.21      -0.94     Beat    70.7
 Jun. 30 2023  -3.31       -3.41      -3.60     Missed  -5.5​
 Mar. 31 2023  -3.38       -3.00      -3.15     Missed  -5
 ​​Dec.        -3.43       -3.37      -4.46     Missed  -32.2
 31 2022                                                
 Sep. 30 2022  -3.18       -4.05      -3.75     Beat    7.4​
 Jun. 30 2022  -3.28       -3.15      -3.60     Missed  -14.3
 Mar. 31 2022  -3.97       -4.20      -2.70     Beat    35.7
 This summary was machine generated May 10 at 11:40 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)